Mother-to-child transmission of HIV: A global perspective

Current Infectious Disease Reports

Volumn 9, Issue 6, 2007, Pages 511-517

  Luzuriaga, Katherine ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

BREAST FEEDING; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; PATHOGENESIS; REVIEW; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 36048988652     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0076-2     Document Type: Review

References (62)

1. Kuhn L, Kasonde P, Sinkala M, et al.: Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis 2005, 41:1654-1661.
2. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al.: Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006, 41:504-508.
3. Taha TE, Graham SM, Kumwenda NI, et al.: Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics 2000, 106:E77.
4. Newell ML, Coovadia H, Cortina-Borja M, et al.: Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004, 364:1236-1243.
5. Walker N, Schwartlander B, Bryce J: Meeting international goals in child survival and HIV/AIDS. Lancet 2002, 360:284-289.
6. Luzuriaga K, Sullivan JL: DNA polymerase chain reaction for the diagnosis of vertical HIV infection. JAMA 1996, 275:1360-1361.
7. Garcia PM, Kalish LA, Pitt J, et al.: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999, 341:394-402.
8. Shearer WT, Quinn TC, LaRussa P, et al.: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997, 336:1337-1342.
9. Ioannidis JP, Abrams EJ, Ammann A, et al.: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000 copies/ml. J Infect Dis 2001, 183:539-545.
10. Van Dyke RB, Korber BT, Popek E, et al.: The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999, 179:319-328.
11. Chouquet C, Richardson S, Burgard M, et al.: Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: bayesian estimation using a mixture. Stat Med 1999, 18:815-833.
12. Lallemant M, Jourdain G, Le Coeur S, et al.: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000, 343:982-991.
13. Goedert JJ, Duliege AM, Amos CI, et al.: High risk of HIV-1 infection for first-born twins. The International Registry of HIV-exposed Twins. Lancet 1991, 338:1471-1475.
14. The mode of delivery and the risk of vertical transmission of Human Immunodeficiency Virus Type 1. A meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med 1999, 340:977-987.
15. European Collaborative Study: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:458-465.
16. Perinatal HIV Guidelines Working Group: Public Health Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. October 12, 2006. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed August 27, 2007.
17. Miotti PG, Taha TE, Kumwenda NI, et al.: HIV transmission through breastfeeding: a study in Malawi. JAMA 1999, 282:744-749.
18. Nduati R, John G, Mbori-Ngacha D, et al.: Effect of breast-feeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000, 283:1167-1174.
19. The Breastfeeding and HIV International Transmission Study Group, Coutsoudis A, Dabis F, et al.: Late postnatal transmission of HIV in breastfed children: an individual patient data meta-analysis. J Infect Dis 2004, 189:2154-2166 [Comment in: J Infect Dis 2004, 189:2149-2153].
20. Bulterys M, Fowler MG, Van Rompay KK, Kourtis AP: Prevention of mother-to-child transmission of HIV-1 through breast-feeding: past, present, and future. J Infect Dis 2004, 189:2149-2153.
21. John-Stewart G, Mbori-Ngacha D, Ekpini R, et al.: Breast-feeding and transmission of HIV-1. J Acquir Immune Defic Syndr 2004, 35:196-202.
22. John GC, Nduati RW, Mbori-Ngacha DA, et al.: Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001, 183:206-212.
23. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180 [Comment in: N Engl J Med 1994, 331:1222-1223, 1223-1225 and N Engl J Med 1995, 332:890-891, 891-892].
24. Wade NA, Birkhead GS, Warren BL, et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998, 339:1409-1414.
25. Cooper ER, Charurat M, Mofenson L, et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002, 29:484-494.
26. Ekouevi DK, Tonwe-Gold B, Dabis F: Advances in the prevention of mother-to-child transmission of HIV-1 infection in resource-limited settings. AIDS Read 2005, 15:479-480, 487-493.
27. Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:795-802.
28. Piot P: AIDS: from crisis management to sustained strategic response. Lancet 2006, 368:526-530.
29. Temmerman M, Quaghebeur A, Mwanyumba F, Mandaliya K: Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS 2003, 17:1239-1242.
30. World Health Organization (WHO): Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. Recommendations for a public health approach. Available at http://www.who.int/hiv/pub/guidelines/adult/en/index.html. Accessed August 27, 2007.
31. World Health Organization (WHO): Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Available at http://www.who.int/hiv/pub/guidelines/art/en/index.html. Accessed August 27, 2007.
32. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004, 351:229-240.
33. Lockman S, Shapiro RL, Smeaton LM, et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007, 356:135-147.
34. Gray GE, Urban M, Chersich MF, et al.: A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 2005, 19:1289-1297.
35. Taha TE, Kumwenda NI, Gibbons A, et al.: Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003, 362:1171-1177.
36. Chaix ML, Ekouevi DK, Rouet F, et al.: Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006, 193:482-487.
37. World Health Organization (WHO): Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach. Available at http://www.who.int/hiv/pub/guidelines/pmtct/en/index.html. Accessed August 27, 2007.
38. Becquet R, Bequet L, Ekouevi DK, et al.: Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Cote d'Ivoire. PLoS Med 2007, 4:e17.
39. John-Stewart GC: When is replacement feeding safe for infants of HIV-infected women? PLoS Med 2007, 4:e30.
40. Coovadia HM, Rollins NC, Bland RM, et al.: Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007, 369:1107-1116.
41. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
42. World Health Organization: WHO HIV and Infant Feeding Technical Consultation Held on behalf of the Inter-agency Task Team (IATT) on Prevention of HIV Infections in Pregnant Women, Mothers and their Infants. Geneva, October 25-27, 2006. Consensus Statement. Available at http://www.who.int/child-adolescent-health/New_Publications/NUTRITION/ consensus_statement.pdf. Accessed August 27, 2007.
43. Graham SM, Holte SE, Peshu NM, et al.: Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007, 21:501-507.
44. Rousseau CM, Nduati RW, Richardson BA, et al.: Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 2004, 190:1880-1888.
45. Shapiro RL, Ndung'u T, Lockman S, et al.: Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005, 192:713-719.
46. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children: Guidelines for the use of antiretroviral agents in pediatric HIV infection. October 26, 2006. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed August 27, 2007.
47. Gortmaker SL, Hughes M, Cervia J, et al.: Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001, 345:1522-1528.
48. Berk DR, Falkovitz-Halpern MS, Hill DW, et al.: Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 2005, 293:2221-2231.
49. Luzuriaga K, Bryson Y, Krogstad P, et al.: Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997, 336:1343-1349.
50. Luzuriaga K, McManus M, Mofenson L, et al.: A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004, 350:2471-2480.
51. Little K, Thorne C, Luo C, et al.: Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. Curr HIV Res 2007, 5:139-153.
52. Moodley D, Moodley P, Moodley J, et al.: Use of rapid tests for perinatal HIV infection in resource-limited settings. J Pediatr Infect Dis 2006, 1:105-110.
53. Rouet F, Inwoley A, Ekouevi DK, et al.: CD4 percentages and total lymphocyte counts as early surrogate markers for pediatric HIV-1 infection in resource-limited settings. J Trop Pediatr 2006, 52:346-354.
54. Richardson BA, Mbori-Ngacha D, Lavreys L, et al.: Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 2003, 77:7120-7123.
55. Ammann A, Burrowes S: Early diagnosis of HIV infection in HIV-exposed infants: can complexity and cost be overcome in resource-poor settings? UCSF Center for HIV Information. March 2007. Available at http://womenchildrenhiv.org/wchiv?page=tp-02-07. Accessed August 27, 2007.
56. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2005, 2:e25.
57. Luzuriaga K, Newell ML, Dabis F, et al.: Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet 2006, 368:511-521.
58. Shaffer N, Chuachoowong R, Mock PA, et al.: Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999, 353:773-780.
59. Lallemant M, Jourdain G, Le Coeur S, et al.: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004, 351:217-228.
60. Jackson JB, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003, 362:859-868.
61. Moodley D, Moodley J, Coovadia H, et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003, 187:725-735.
62. Petra Study Team: Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002, 359:1178-1186 [Comment in: Lancet 2002, 359:1168-1169; Lancet 2002, 360:1974-1975; Lancet 2004; 363:243; author reply 244].